BNTC icon

Benitec Biopharma

12.90 USD
+0.35
2.79%
Updated Apr 3, 3:21 PM EDT
1 day
2.79%
5 days
-5.70%
1 month
3.86%
3 months
6.61%
6 months
31.50%
Year to date
6.79%
1 year
132.85%
5 years
-77.81%
10 years
-90.48%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

275% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 4

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

89% more capital invested

Capital invested by funds: $127M [Q3] → $240M (+$113M) [Q4]

20% more funds holding

Funds holding: 25 [Q3] → 30 (+5) [Q4]

48.06% less ownership

Funds ownership: 129.88% [Q3] → 81.82% (-48.06%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
40%
upside
Avg. target
$23
78%
upside
High target
$28
117%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
26% 1-year accuracy
18 / 70 met price target
117%upside
$28
Buy
Reiterated
24 Mar 2025
Citizens Capital Markets
Silvan Tuerkcan
31% 1-year accuracy
10 / 32 met price target
40%upside
$18
Market Outperform
Reiterated
18 Mar 2025

Financial journalist opinion

Negative
24/7 Wall Street
1 day ago
Insiders Are Loving These 5 Tech and Biotech Stocks
After struggling through a rough patch, the biotech industry seems to be staging a comeback.
Insiders Are Loving These 5 Tech and Biotech Stocks
Neutral
GlobeNewsWire
1 week ago
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital.
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
Positive
Zacks Investment Research
1 month ago
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable
Neutral
GlobeNewsWire
1 month ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024.
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Positive
Zacks Investment Research
2 months ago
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Positive
Zacks Investment Research
3 months ago
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?
Positive
Zacks Investment Research
3 months ago
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
Neutral
GlobeNewsWire
4 months ago
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
Charts implemented using Lightweight Charts™